Persistence
|
T-Cells
|
Clinical Biomarker
|
Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer
|
Science Translational Medicine, 2023
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Response Potency
|
CAR-T
|
Preclinical Discovery
|
The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer
|
Nature Communications, 2023
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Response Potency
|
T-Cells
|
Preclinical Discovery
|
Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity
|
Science Immunology, 2023
|
IsoCode Single-Cell Adaptive Immune:
Mouse T-cells Protocol
|
Response
|
T-Cells
|
Preclinical Discovery
|
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models
|
Science Translational Medicine, 2023
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Response Potency
|
NK Cells
|
Preclinical Discovery
|
Synapse-tuned CARs enhance immune cell anti-tumor activity
|
Nature Biotechnology, 2023
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Response
|
NK Cells
|
Clinical Biomarker
|
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition
|
Journal for Immunotherapy of Cancer, 2022
|
IsoCode Single-Cell Adaptive Immune: Human NK Cell
|
Response
|
T-Cells
|
Clinical Biomarker
|
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
|
Journal for Immunotherapy of Cancer, 2022
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Persistence Potency
|
CAR-T
|
Preclinical Discovery
|
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors
|
Cancer Immunology Research, 2022
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Potency
|
T-Cells
|
Manufacturing & Product QC
|
Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing
|
Frontiers in Medical Technology, 2022
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Potency
|
T-Cells
|
Preclinical Discovery
|
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
|
Frontiers in Immunology, 2022
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Persistence Potency
|
CAR-T
|
Preclinical Discovery
|
A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
|
Nature Communications, 2022
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Response Persistence
|
CAR-T
|
Clinical Biomarker
|
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
|
Science Advances, 2022
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Response Potency
|
CAR-T
|
Clinical Biomarker
|
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies
|
Cytotherapy, 2022
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Potency Survival
|
CAR-T
|
Preclinical Discovery
|
Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL | Blood | American Society of Hematology
|
Blood, 2022
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Potency Survival
|
TCR-T
|
Preclinical Discovery
|
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
|
Cancers, 2022
|
IsoCode Single-Cell Adaptive Immune: TCR‑T
|
Response
|
Myeloid Cells
|
Clinical Biomarker
|
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system
|
Oncoimmunology, 2022
|
IsoCode Single-Cell Innate Immune: Human Monocyte Using Membrane Stain
|
Response
|
T-Cells
|
Clinical Biomarker
|
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
|
JITC, 2022
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Response Survival
|
T-Cells
|
Clinical Biomarker
|
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer
|
Advances in Radiation Oncology, 2021
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Potency
|
CAR-T
|
Preclinical Discovery
|
Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice
|
JCI Insight, 2021
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Persistence Potency
|
CAR-T
|
Preclinical Discovery
|
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
|
Journal for Immunotherapy of Cancer, 2021
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Response Survival
|
T-Cells
|
Clinical Biomarker
|
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy
|
Blood Advances, 2021
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Potency
|
TILs
|
Manufacturing & Product QC, Clinical Biomarker
|
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
|
Nature Medicine, 2021
|
IsoCode Single-Cell Adaptive Immune: Human T-Cell
|
Potency
|
CAR-T
|
Manufacturing & Product QC, Clinical Biomarker
|
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
|
Nature Medicine, 2021
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Efficacy
|
NK Cells
|
Preclinical Discovery
|
Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation
|
Communications Biology, 2021
|
IsoCode Single-Cell Adaptive Immune: Human NK Cell
|
Fitness Response
|
T-Cells
|
Preclinical Discovery, Clinical Biomarker
|
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
|
Blood, 2021
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Response Survival
|
T-Cells
|
Clinical Biomarker
|
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
|
Journal of Clinical Oncology, 2021
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Potency
|
NK Cells
|
Preclinical Discovery
|
Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors
|
Cytotherapy, 2021
|
IsoCode Single-Cell Adaptive Immune: Human NK Cell
|
Potency
|
NK Cells
|
Preclinical Discovery
|
NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells
|
Frontiers in Immunology, 2021
|
IsoCode Single-Cell Adaptive Immune: Human NK Cell
|
Potency
|
CAR-T
|
Preclinical Discovery
|
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity
|
Molecular Therapy, 2021
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Potency
|
T-Cells
|
Preclinical Discovery, Clinical Biomarker
|
Use of Multi-Site Radiation Therapy for Systemic Disease Control
|
International Journal of Radiation Oncology, Biology, Physics, 2021
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Response
|
T-Cells
|
Clinical Biomarker
|
Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer
|
Clinical Cancer Research, 2020
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Potency
|
T-Cells
|
Preclinical Discovery
|
Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice
|
Frontiers in Immunology, 2020
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Persistence Potency
|
NK Cells
|
Preclinical Discovery
|
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes in vivo Persistence and Enhances Anti-tumor Activity
|
Cell Stem Cell, 2020
|
IsoCode Single-Cell Adaptive Immune: Human NK Cell
|
Potency
|
CAR-T
|
Preclinical Discovery
|
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
|
Leukemia, 2020
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Persistence Potency
|
CAR-T
|
Preclinical Discovery
|
Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice
|
Gastroenterology, 2020
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Persistence Potency
|
T-Cells, NK Cells
|
Preclinical Discovery, Clinical Biomarker
|
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
|
Nature Communications, 2020
|
IsoCode Single-Cell Adaptive Immune: Human PBMC
|
Potency
|
CAR-T
|
Preclinical Discovery
|
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
|
Blood Advances, 2019
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Response
|
CAR-T
|
Clinical Biomarker, Manufacturing & Product QC
|
Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL
|
Blood, 2018
|
IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
|
Potency
|
T-Cells
|
Preclinical Discovery, Clinical Biomarker
|
A Kinetic Investigation of Interacting, Stimulated T Cells Identifies Conditions for Rapid Functional Enhancement, Minimal Phenotype Differentiation, and Improved Adoptive Cell Transfer Tumor Eradication
|
PLOS One, 2018
|
IsoCode Single-Cell Adaptive Immune: Human PBMC with PMA & Ionomycin
|